Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obalon Therapeutics Inc    OBLN

OBALON THERAPEUTICS INC (OBLN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
2.23(c) 2.2(c) 2.2(c) 2.01(c) 2.01(c) Last
46 325 18 858 19 761 57 159 70 398 Volume
+1.83% -1.35% 0.00% -8.64% 0.00% Change
More quotes
Financials (USD)
Sales 2018 13,6 M
EBIT 2018 -37,7 M
Net income 2018 -38,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 21,7 M
EBIT 2019 -34,6 M
Net income 2019 -35,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 2,59x
Capi. / Sales2019 1,63x
Capitalization 35,3 M
More Financials
Company
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss.Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then... 
More about the company
Surperformance© ratings of Obalon Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OBALON THERAPEUTICS INC
07/13OBALON THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
07/13OBALON THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation o..
AQ
06/14OBALON THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders, F..
AQ
06/06OBALON THERAPEUTICS : FDA Letter to Health Care Providers Related to Potential R..
AQ
06/05OBALON THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation o..
AQ
06/05Obalon Announces Upcoming Conference Presentation
GL
05/17Obalon Announces Upcoming Conference Presentation
GL
05/10OBALON THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
05/10OBALON THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
AQ
05/10Obalon Announces First Quarter 2018 Financial Results
GL
More news
Sector news : Medical Devices & Implants
07/17BAXTER INTERNATIONAL : Releases FDA Warning Letter for 2017 Inspection in India
DJ
07/11Brazil prosecutors allege jailed GE executive helped company partake in medic..
RE
07/11MEDTRONIC : Gets FDA Approval for Less-Invasive Heart Pump Implant Procedure
DJ
07/09BECTON DICKINSON AND : Completes Acquisition of TVA Medical
DJ
06/29ESSILOR INTERNATIONAL : Luxottica, Essilor extend deadline for merger pending Ch..
RE
More sector news : Medical Devices & Implants
Latest Tweets
07/17Obalon Therapeutics $OBLN Sets New 12-Month Low at $2.01  
07/15Obalon Therapeutics $OBLN Rating Lowered to Sell at Zacks Investment Research.. 
07/12Zacks Investment Research Lowers Obalon Therapeutics $OBLN to Sell  
07/07Zacks: Analysts Expect Obalon Therapeutics Inc $OBLN to Announce -$0.50 EPS
1
07/07Obalon Therapeutics $OBLN Lifted to Buy at ValuEngine  
More tweets
Qtime:27
News from SeekingAlpha
06/22After Hours Gainers / Losers (06/22/2018) 
06/22Midday Gainers / Losers (06/22/2018) 
06/22HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/22/2018) 
06/06Obalon quick to distance itself from FDA advisory on intragastric balloon ris.. 
05/12Obalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings C.. 
Chart OBALON THERAPEUTICS INC
Duration : Period :
Obalon Therapeutics Inc Technical Analysis Chart | OBLN | US67424L1008 | 4-Traders
Technical analysis trends OBALON THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,25 $
Spread / Average Target 111%
EPS Revisions
Managers
NameTitle
Andrew P. Rasdal President, Chief Executive Officer & Director
Kim P. Kamdar Chairman
Kelly Huang Chief Operating Officer
William John Plovanic Chief Financial Officer & Secretary
Mark Brister Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
OBALON THERAPEUTICS INC-69.59%35
STRYKER CORPORATION13.74%65 138
SMITH & NEPHEW3.57%15 564
WRIGHT MEDICAL GROUP NV14.82%2 700
JAPAN LIFELINE CO., LTD.23.09%2 384
GLAUKOS CORP65.73%1 471